Compare SoundHound AI Inc (SOUN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs TransMedics Group Inc — how do they compare? SoundHound AI Inc trades at $5.39 (market cap $2.45B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: SoundHound AI Inc and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoundHound AI Inc for 23 Days and TransMedics Group Inc for 24 Days on average.
| SOUN | TMDX | |
|---|---|---|
Market Cap | $2.45B | $2.74B |
Volume | 16,881,989 | 949,331 |
Sector | Technology | Health |
52-Week High | $21.40 | $150.42 |
52-Week Low | $5.52 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $2.25B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $5.39, down 4.26% on the day, with the stock showing bearish technical signals despite recent earnings beats. The company maintains strong revenue growth with 2026 projections at $203M but faces significant net losses (-$137M in 2026). Analyst sentiment remains positive with a 75% buy rating and $9.33 consensus price target, while recent news highlights expansion in automotive and restaurant voice AI deployments.
The stock presents a high-risk, high-reward opportunity with strong growth potential in voice AI markets but faces profitability challenges and negative cash flow trends. Key catalysts include continued revenue expansion and new product launches, while risks include integration challenges and persistent losses requiring careful monitoring of execution milestones.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
